Our Department of Biostatistics is recognized as a worldwide leader in research and practice. Members of our faculty are interested both in the development of statistical methodology and application of statistics in applied research.
Coronavirus Affects Everyone: The Department of Biostatistics Responds
Around the world, several clinical trials are being conducted to find treatments for COVID-19. In particular, five clinical trials are currently evaluating the efficacy and safety of remdesivir, which was identified by the World Health Organization (WHO) as the most promising agent to treat COVID-19. The selection of appropriate endpoints is critical to the success of these trials, but the endpoints adopted in the current trials do not capture the entire clinical experience of a patient. Indeed, very different endpoints were adopted by each of the five trials, even for patients with the same severity of the disease. Drs. Danyu Lin and Donglin Zeng in the Department of Biostatistics proposed the use of a common endpoint for all remdesivir trials, which would allow researchers to evaluate the efficacy of treatments by a common criterion, which is particularly important when combining evidence from different trials.
Research Strengths
- Development of new statistical methods to address pressing issues in medicine and public health sciences
- Design of innovative clinical trials that allow faster evaluation of new therapeutic agents
- Collaborative work focused upon important public health concerns, including infectious diseases, cancer, cardiovascular disease, obesity and drinking water safety
- Utilization of strong quantitative skills to improve the health of human beings around the globe
Message from the Chair
Department Spotlight
